Interestingly, several preclinical studies in breast cancer showed the use of selective COX-2 inhibitors (celecoxib, rofecoxib, etodolac) could efficiently block breast tumor growth and metastasis [16–22]. Here, PTGS2 is linked to breast carcinoma.